Lyme disease word cloud. From

Pfizer and Valneva Join Forces on Lyme Disease Vaccine

The engineered protein vaccine VLA15 induces multiple antibodies in a Phase II trial and has the potential to provide protection against the different bacteria that cause Lyme disease in North America and Europe.

Diagram of the VLA vaccine strategy. The vaccine has 3 engineered proteins. Each contains 2 forms of OspA from different Borrelia bacterial serotypes and a lipid modification to enhance immunogenicity. The OspA proteins are shown as octagons and the antibodies induced by the vaccine as the Y-shapes. The linker connecting the two OspA proteins is shown as a gray line and the lipid is represented by wavy lines. [Credit: Nancy R. Gough, Ph.D. BioSerendipity, LLC]


Also of Interest

About the author

Scientist, editor, and writer with a PhD in Pharmacology

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store